Ilofotase alfa now belongs to Ambrose Healthcare, a UK-headquartered rare disease company. On 20 October 2026, Ambrose said it had acquired 100 per cent of the shares of AM-Pharma. The Dutch company, based in Utrecht, developed the drug. The deal is complete rather than pending, according to the Ambrose release on GlobeNewswire.
AM-Pharma’s shareholders can receive up to €161 million. However, most of that figure is contingent on future commercial success. Ambrose plans to develop the enzyme for hypophosphatasia (HPP), a rare inherited bone disease. The upfront payment was not disclosed.
Who Owns Ilofotase Alfa After the AM-Pharma Deal?
Ambrose now owns AM-Pharma outright, and with it the company’s lead asset. The release lists ilofotase alfa as the third clinical-stage programme in the Ambrose portfolio. The other two are renzapride and VAL401.
One territory question remains open. In September 2021, AM-Pharma granted Kyowa Kirin exclusive rights in Japan. The 2021 announcement centred on sepsis-associated acute kidney injury. However, it did not limit the rights to that indication, and it did not mention HPP. Kyowa Kirin paid €20 million upfront in a deal worth up to €245 million.
The Ambrose release does not mention Kyowa Kirin. A search on 21 October 2026 found no public statement on whether that Japanese licence remains in force. Therefore, the exact split of rights in Japan cannot be confirmed from public sources.
What Ambrose Is Paying for AM-Pharma
Upfront, milestones and royalties
The release describes three parts to the consideration. First, there is an upfront payment. Second, there are milestone payments contingent on commercialising the HPP treatment. Third, there are royalties on future sales.
The €161 million ceiling covers all three. Fierce Biotech converted the figure to $181 million but did not state an exchange rate. Ambrose has not said how much is paid now and how much depends on sales.
What has not been disclosed
“Other financial terms are not disclosed,” the release states. It does not name the form of consideration, such as cash or shares. Nor does it name any financial or legal advisers.
Both parties are private companies. As a result, there is no share price reaction to report.
Deal terms at a glance
| Term | Detail |
|---|---|
| Buyer | Ambrose Healthcare Ltd (UK) |
| Target | AM-Pharma (Utrecht, the Netherlands) |
| Asset | Ilofotase alfa, recombinant human alkaline phosphatase |
| Structure | Acquisition of 100 per cent of the shares |
| Upfront | Not disclosed |
| Milestones | Contingent on commercialisation in HPP; amounts not disclosed |
| Royalties | On future sales; rates not disclosed |
| Total announced value | Up to €161 million |
| Status | Completed, announced 20 October 2026 |
What Ambrose Gets: The Asset and Its Data
Ilofotase alfa is a recombinant human alkaline phosphatase. In HPP, it would act as an enzyme replacement therapy. The release calls the programme “Phase 2-ready”. It also says the drug has orphan drug designation for HPP from the FDA and the EMA.
The main HPP evidence comes from a small open-label study. In October 2023, AM-Pharma reported phase 1b data in 12 adults with HPP. Patients received a single intravenous dose of 0.8 mg/kg or 3.2 mg/kg.
Two disease biomarkers fell after dosing. Pyridoxal 5’-phosphate (PLP) fell by up to 35 per cent at the low dose. At the high dose, it fell by up to 66 per cent. Inorganic pyrophosphate (PPi) fell by up to 36 per cent and 77 per cent respectively. The company described the drug as well tolerated.
These are biomarker results from single doses over 10 days. They do not show a clinical benefit on pain, mobility or fractures. That question would fall to later studies.
A drug with a long history
Ambrose also inherits a large human safety record. The release cites a safety database “spanning nearly 700 patients”. Most of that experience comes from kidney injury trials rather than HPP.
The drug has changed hands and direction before. In May 2015, Pfizer paid $87.5 million for a minority stake and an option to buy AM-Pharma. Up to $512.5 million more was tied to exercising that option and a product launch. Fierce Biotech reported that Pfizer walked away in 2018 after phase 2 kidney injury data.
AM-Pharma then ran the phase 3 REVIVAL study in sepsis-associated acute kidney injury. In October 2022, the company said the study had been stopped for futility on its primary endpoint. The data monitoring committee reviewed the first 400 patients and found no safety concerns.
The company later tested the drug in kidney damage after cardiac surgery. That phase 2 study randomised 244 patients. Results published in Intensive Care Medicine in 2026 showed no significant reduction in kidney injury. Meanwhile, the HPP programme continued in parallel.
Why Ambrose Says It Bought AM-Pharma
Ambrose frames the deal as buying an asset where the costly early work is already done. Toby Wilson Waterworth, CEO of Ambrose Healthcare, commented on the fit. “It is exactly the kind of asset we built Ambrose to develop,” he said.
He added that the deal gives Ambrose “a European platform”. He described this as infrastructure “that would have taken us some time to establish on our own”.
Clarissa Sowemimo-Coker, Chief Strategy Officer of Ambrose Healthcare, said the company grows “opportunistically, with financial discipline”. She said Ambrose “will continue to evaluate further acquisitions and other opportunities”.
For the seller, Dr Juliane Bernholz, CEO of AM-Pharma, pointed to patient need. She said adults with HPP face “debilitating symptoms such as severe pain, fatigue, and muscle and bone weakness”. According to the release, AM-Pharma’s data in adult HPP “support advancing the program into Phase 2”.
Where Ilofotase Alfa Fits in the HPP Landscape
The release targets a clear gap. It states that up to 45 per cent of patients are diagnosed with adult-onset HPP. It adds that “there is currently no approved treatment for these HPP patients.”
The two companies in this field count patients differently. AstraZeneca says approximately 80 per cent of people living with HPP are adults. That figure describes current age. The Ambrose figure instead refers to patients diagnosed with adult-onset disease. The two numbers therefore measure different things and should not be compared directly.
The existing therapy is Strensiq (asfotase alfa) from Alexion, AstraZeneca Rare Disease. Its UK summary of product characteristics covers patients of all ages with paediatric-onset HPP. It treats the bone manifestations of the disease. The medicine was authorised under exceptional circumstances.
Meanwhile, AstraZeneca has a newer enzyme in late development. On 18 September 2026, it said the FDA had accepted a licence application for efzimfotase alfa with priority review. The proposed indication covers patients with HPP aged 2 years and older. AstraZeneca expects an FDA decision in the first half of 2027.
What HICKORY shows about adult-onset HPP
AstraZeneca’s HICKORY phase 3 results, published on 11 October 2026, are directly relevant. The trial enrolled 124 adolescents and adults, including 64 with adult-onset disease. It missed statistical significance on its primary endpoint, the six-minute walk test.
In the adult-onset subgroup, the difference versus placebo was minus 2.70 metres. AstraZeneca attributed the overall result largely to “better-than-expected results” in the adult-onset placebo group. By contrast, fatigue scores, a key secondary endpoint, showed a nominally significant improvement.
This matters for Ambrose. Adult-onset HPP is the group its release highlights. HICKORY suggests that walking distance may be a hard endpoint to move in these patients. Ambrose has not said which endpoint its pivotal study would use.
What to Watch Next for Ilofotase Alfa
Several questions remain unanswered as at 21 October 2026. First, Ambrose has not given a start date for the next HPP study. The release refers only to “an agreed development plan built around a single pivotal study.”
Second, the upfront payment and milestone amounts are undisclosed. A guide to biotech deal structure explains why headline totals often overstate the cash paid at signing.
Third, the status of Kyowa Kirin’s Japanese rights is unclear. Fourth, the FDA decision on efzimfotase alfa, expected in the first half of 2027, will shape the competitive field.
This is a small deal by 2026 standards. For comparison, LSDN listed every $1 billion-plus biotech deal earlier in 2026. Even so, it shows a UK buyer acquiring a European asset that Pfizer once passed on.
